Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

Fluctuations related to treatment may occur in 5%-15% of patients, corresponding to relapses during the plateau phase or after initiating the recovery phase. In such cases, retreatment may be ...

Anito-cel is partnered with Kite, a Gilead Company. The Phase 2 iMMagine-1 data are from a May 1, 2025 data cutoff date, including all 117 patients with a median follow-up of 12.6 months and a ...

(RTTNews) - Arcellx, Inc. (ACLX), a biotechnology company, Wednesday announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients ...

To further our strategic development plan, preparing to initiate the open-label tanruprubart FORWARD study, measuring pharmacokinetics, pharmacodynamics, early efficacy in week 1, and safety in up to ...

Ciara Freeman, MD, PhD, discusses anito-cel's unique functions and benefits for treating multiple myeloma. In an interview with Targeted Oncology TM, Ciara Freeman, MD, medical oncologist at Moffitt ...

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study De ...

ANX1502, part of Annexon’s Phase 1 program ... expenditure forecasts and penetration assumptions for Annexon’s Guillain-Barre Syndrome program in the U.S. and European markets.

ANX1502, part of Annexon’s Phase 1 program, has shown positive safety and tolerability ... expenditure forecasts and penetration assumptions for Annexon’s Guillain-Barre Syndrome program in the U.S.

May 09, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharm Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related ...